scholarly journals PS1100 CONGENITAL FACTOR V DEFICIENCY FROM COMPOUND HETEROZYGOUS MUTATIONS WITH A NOVEL MUTATION C.2426DEL (P.PRO809HISFS∗2) IN THE F5 GENE

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 499
Author(s):  
C.-H. Park ◽  
M.-S. Park ◽  
K.-O. Lee ◽  
S.-H. Kim ◽  
Y.S. Park ◽  
...  
Medicine ◽  
2020 ◽  
Vol 99 (5) ◽  
pp. e18947
Author(s):  
Chang-Hun Park ◽  
Min-Seung Park ◽  
Ki-O Lee ◽  
Sun-Hee Kim ◽  
Young Shil Park ◽  
...  

Haemophilia ◽  
2006 ◽  
Vol 12 (2) ◽  
pp. 172-178 ◽  
Author(s):  
N. YAMAKAGE ◽  
M. IKEJIRI ◽  
K. OKUMURA ◽  
A. TAKAGI ◽  
T. MURATE ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Jianping Jiang ◽  
Jinwei Huang ◽  
Jianlei Gu ◽  
Xiaoshu Cai ◽  
Hongyu Zhao ◽  
...  

Abstract Background Spinal muscular atrophy (SMA) is a rare neuromuscular disorder threating hundreds of thousands of lives worldwide. And the severity of SMA differs among different clinical types, which has been demonstrated to be modified by factors like SMN2, SERF1, NAIP, GTF2H2 and PLS3. However, the severities of many SMA cases, especially the cases within a family, often failed to be explained by these modifiers. Therefore, other modifiers are still waiting to be explored. Case presentation In this study, we presented a rare case of SMA discordant family with a mild SMA male patient and a severe SMA female patient. The two SMA cases fulfilled the diagnostic criteria defined by the International SMA Consortium. With whole exome sequencing, we confirmed the heterozygous deletion of exon7 at SMN1 on the parents’ genomes and the homozygous deletions on the two patients’ genomes. The MLPA results confirmed the deletions and indicated that all the family members carry two copies of SMN2, SERF1, NAIP and GTF2H2. Further genomic analysis identified compound heterozygous mutations at TLL2 on the male patient’s genome, and compound heterozygous mutations at VPS13A and the de novo mutation at AGAP5 on female patient’s genome. TLL2 is an activator of myostatin, which negatively regulates the growth of skeletal muscle tissue. Mutation in TLL2 has been proved to increase muscular function in mice model. VPS13A encodes proteins that control the cycling of proteins through the trans-Golgi network to endosomes, lysosomes and the plasma membrane. And AGAP5 was reported to have GTPase activator activity. Conclusions We reported a case of SMA discordant family and identified mutations at TLL2, VPS13A and AGAP5 on the patients’ genomes. The mutations at TLL2 were predicted to be pathogenic and are likely to alleviate the severity of the male SMA patient. Our finding broadens the spectrum of genetic modifiers of SMA and will contribute to accurate counseling of SMA affected patients and families.


1989 ◽  
Vol 19 (6) ◽  
pp. 331-334 ◽  
Author(s):  
C. Manotti ◽  
R. Quintavalla ◽  
M. Pini ◽  
M. Jeran ◽  
M. Paolicelli ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4444-4444
Author(s):  
Natalia Dixon ◽  
Anita Smith ◽  
Hernan Sabio

Abstract Abstract 4444 Background Congenital factor V deficiency is one of the rare bleeding disorders and is identified in approximately 1/1,000,000 persons. Current management relies on the use of plasma preparations to replace factor V. The clinical variability and limited therapeutic options contribute to make congenital factor V deficiency a challenging disorder. Case report An 18 years old male was diagnosed with severe congenital factor V deficiency (1% activity) after prolonged bleeding following trauma. He reported a past history consistent with hemarthroses and episodes of soft-tissue bleeding. After receiving a cumulative total of 67 units of plasma during his life he developed respiratory symptoms including dyspnea and chest pain. These symptoms worsened during subsequent infusions. The patient developed persistent bleeding associated with onychocryptosis and a periungual infection which was not responsive to local hemostatic measures. Because of his intolerance of plasma, he was treated with recombinant factor VIIa (rVIIa) at a dose of 50 micrograms/kg resulting in effective hemostasis. Subsequently he underwent a Syme amputation with permanent nail removal and ablation with resection of the tuft of the distal phalanx. During the perioperative period the patient received infusions of rVIIa (50 micrograms/kg) resulting in excellent hemostasis. The patient also experienced a very good response to rVIIa infusions at the same dose for the treatment of an expanding soft-tissue hematoma following accidental trauma to the posterior cervical area. The patient has tolerated the rVIIa infusions without difficulty. Discussion We report the successful use of rVIIa to control soft-tissue bleeding and to provide hemostasis during a surgical procedure in a patient with congenital factor V deficiency. Limited previous experience with the use of rVIIa in the management of congenital factor V deficiency includes its use for dental procedures as reported by Altisent (Haemophilia 6:408, 2000) and for synovectomy as reported by Gonzalez-Boullosa (Haemophilia 11:167, 2005). Although a mechanism of action has not been identified, it can be speculated that residual platelet factor V may become more available through rVIIa leading to increased thrombin generation. Conclusion rVIIa infusions resulted in improved hemostasis in a patient with severe congenital factor V deficiency. Disclosures: Off Label Use: recombinant factor VIIa used to control bleeding in congenital factor V deficiency.


Sign in / Sign up

Export Citation Format

Share Document